Steve Harvey/LinkedIn
Sep 19, 2025, 06:06
Aspirin as Precision Medicine? Steve Harvey Highlights Evidence for PIK3-Mutated Colorectal Cancer Patients
Steve Harvey, CEO of Camena Bioscience, shared a post on LinkedIn:
“A very interesting study indicates that Aspirin could be a precision medicine for colorectal cancer.
The study, which was publicised in the New England Journal of Medicine, studied 3500 patients with colorectal cancer.
~40% of those patients had mutations in genes associated with the PIK3 signalling pathway.
Those patients with the PIK3 associated mutations and taking aspirin, were 55% less likely to have the cancer return than those on placebo.
P.s. I’ll add the Guardian article to the comments.”
You can read the full article here.
More posts featured in Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM